#ASCO22 – RCT: Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer.

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Trastuzumab Deruxtecan Cuts Risk of Disease Progression or Death by 50% for Patients With HER2-Low Metastatic Breast Cancer – AJMC

Commentary on Twitter

DESTINY-Breast04: In a phase 3 trial, trastuzumab deruxtecan resulted in longer progression-free and overall survival than the physician’s choice of chemo among patients with HER2-low breast cancer. #ASCO22 https://t.co/bgheQ1yolb pic.twitter.com/nfRMcIh9Ly

— NEJM (@NEJM) June 5, 2022